Skip to main content

Advertisement

Table 2 Fold changes of molecular apocrine-signature genes following treatment with AR and MEK inhibitors.

From: Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer

Tx
Gene
MDA-CI-2 MDA-FLU MDA-FLU-CI MDA-CI-10 HCC-CI-2 HCC-FLU HCC-FLU-CI HCC-CI-10
PIP 0.71 0.63 0.24 0.19 0.65 0.4 0.26 0.42
DUSP6 0.6 0.125 0.01 0.01 0.16 0.98 0.18 0.02
S100A8 1.2 0.09 0.06 0.45 1.3 0.86 0.77 0.68
FOXA1 1.2 0.67 0.5 0.9 1.08 0.71 0.58 0.68
TFAP2 1 0.43 0.15 0.5 1.61 0.53 0.68 1.69
SOX11 1.3 0.56 0.32 0.63 1.97 1 1.95 2.33
BANP 1 0.78 0.9 1 1.16 0.94 1.09 1.07
PER2 1.27 0.85 1.62 1.74 0.93 0.79 0.9 0.59
TFF3 1.71 0.55 0.43 0.73 1.23 1.23 1.72 1.43
AZGP1 1.36 1.29 0.73 1 1.3 1.78 2.23 1.21
  1. * The average fold change to control for three biological replicate experiments is shown for each treatment group. Tx, treatment group; MDA, MDA-MB-453 and HCC, HCC-1954. FLU, flutamide at 25 µM and 40 µM concentrations for MDA-MB-453 and HCC-1954, respectively. CI-2, CI-1040 at 2 µM and CI-10: CI-1040 at 10 µM. Standard deviation of the fold changes: <0.05.